keyword
MENU ▼
Read by QxMD icon Read
search

Tardive dyskinesia

keyword
https://www.readbyqxmd.com/read/29449008/tardive-dyskinesia-out-of-the-shadows
#1
REVIEW
Robert A Hauser, Daniel Truong
The approvals of the first two medications, valbenazine and deutetrabenazine, to treat tardive dyskinesia have ushered in a new era in neuropsychiatric care. Tardive syndromes are defined as delayed onset, persistent movement disorders or sensory phenomena that occur in association with exposure to dopamine receptor blocking agents (DRBAs). Their underlying pathophysiology remains to be fully elucidated, but clinicians can conceptualize tardive syndromes as persistent dopamine supersensitivity states. Tardive syndromes can potentially cause distress, disfigurement, embarrassment, and dysfunction, and are often permanent...
February 5, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29439776/clinical-risk-factors-for-the-development-of-tardive-dyskinesia
#2
REVIEW
Marco Solmi, Giorgio Pigato, John M Kane, Christoph U Correll
BACKGROUND: Tardive dyskinesia (TD) is a severe condition that can affect almost 1 out of 4 patients on current or previous antipsychotic treatment, including both first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). While two novel vesicular monoamine transporter inhibitors, deutetrabenazine and valbenazine, have shown acute efficacy for TD, the majority of patients do not remit, and TD appears to recur once treatment is withdrawn. Hence, prevention of TD remains a crucial goal...
February 5, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433811/tardive-dyskinesia-epidemiology
#3
REVIEW
Anelyssa D'Abreu, Umer Akbar, Joseph H Friedman
The term tardive syndrome (TS) encompasses a few different phenomenologic conditions, some of which occur in isolation and others in association with each other. This, along with the unusual confound for a drug side effect, in which increased use of the drug improves the problem, and the need for most patients to continue taking the offending drug, makes understanding the epidemiology difficult and unreliable. While the change from the "first generation" to the "second generation" of antipsychotic drugs is generally believed to have reduced the incidence of TS, prospective research studies have not supported that contention...
February 5, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433810/the-nosology-of-tardive-syndromes
#4
Karen Frei, Daniel D Truong, Stanley Fahn, Joseph Jankovic, Robert A Hauser
Since the original description of side effects of neuroleptics, different terminologies and definitions for tardive dyskinesia (TD) and tardive syndrome (TS) have been used by different authors, and often these two terms have been used interchangeably. This paper proposes a nosology designed to define and clarify various terms and phenomenologies within the TS spectrum. We propose to use the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements, as well as to the analogous repetitive movements that can appear in the limbs, trunk, or pelvis...
February 6, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433809/future-directions-in-tardive-dyskinesia-research
#5
REVIEW
Jonathan M Meyer
Tardive dyskinesia (TD) research is at a crossroads because of renewed interest in this syndrome following the successful development and regulatory approval of two novel vesicular monoamine transport 2 (VMAT2) inhibitors. Despite these clinical advances, significant lacunae exist in the knowledge base of TD pathophysiology, prognosis, and epidemiology. Moreover, conflicting definitions of TD as either a syndrome that encompasses a broad array of related phenomena or as a specific subset of tardive syndromes are an impediment to both clinical and basic science research, and to educational efforts targeting nonspecialist clinicians...
February 5, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433808/vmat2-inhibitors-for-the-treatment-of-tardive-dyskinesia
#6
REVIEW
Laura M Scorr, Stewart A Factor
Tardive dyskinesia (TD) is an often disabling hyperkinetic movement disorder caused by exposure to dopamine receptor blocking agents. Although initially thought to most commonly occur with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide. Increased prescribing of these agents as well as low rates of remission have contributed to a rising prevalence of TD. Although this condition was described nearly 60 years ago, it is only within the past year that two novel therapeutic agents were FDA approved...
February 5, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433807/deep-brain-stimulation-for-tardive-syndromes-systematic-review-and-meta-analysis
#7
REVIEW
Antonella Macerollo, Günther Deuschl
Among the broad entity of tardive syndromes, tardive dystonia and classical tardive dyskinesia sometimes require advanced treatments like deep brain stimulation of the globus pallidus internum (Gpi-DBS) or the subthalamic nucleus (STN-DBS). This systematic review has analyzed the currently available literature reporting cases with either tardive dystonia or dyskinesia treated with DBS. The key words for the literature search included all tardive syndromes and "deep brain stimulation." Thirty-four level VI studies and one level II study with 117 patients were included...
February 5, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433806/non-vmat2-inhibitor-treatments-for-the-treatment-of-tardive-dyskinesia
#8
REVIEW
Chih-Chun Lin, William G Ondo
Although VMAT2-inhibitors are now established as first-line treatment for tardive dyskinesia, not all patients respond to, or tolerate them. Numerous other agents have been adopted to treat tardive dyskinesia, but with variable results and generally lower quality methodologic reports. Amantadine is the most promising but benzodiazepines, branched chain neutral amino acids, Vitamin B6, several nutraceuticals, and botulinum toxin injections might help some patients. In all cases, better placebo controlled trials are needed before definitive recommendations can be made...
February 5, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29427000/tardive-dyskinesia-associated-with-atypical-antipsychotics-prevalence-mechanisms-and-management-strategies
#9
REVIEW
Katharina Stegmayer, Sebastian Walther, Peter van Harten
All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the prevalence and etiology of and management strategies for TD associated with AAPs. TD prevalence rates varied substantially between studies, with an estimated prevalence of around 20% in patients using AAPs...
February 9, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29409162/antipsychotic-reduction-and-or-cessation-and-antipsychotics-as-specific-treatments-for-tardive-dyskinesia
#10
REVIEW
Hanna Bergman, John Rathbone, Vivek Agarwal, Karla Soares-Weiser
BACKGROUND: Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Various strategies have been examined to reduce a person's cumulative exposure to antipsychotics. These strategies include dose reduction, intermittent dosing strategies such as drug holidays, and antipsychotic cessation...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29403138/amisulpride-reexposure-and-tardive-dyskinesia
#11
Ajeet Sidana
To highlight the association between amisulpride and onset of tardive dyskinesia (TD) in patient suffering with psychosis not otherwise specified (NOS), who has already been treated with amisulpride for many years. A 40-year-old female suffering with psychosis NOS since 19 years presented with recurrence of positive symptoms in the form of delusion of persecution, ideas of grandiosity since last 3 months. She was treated with amisulpride up to 400 mg/day and developed involuntary oro-buccal-lingual movement within 2 months of amisulpride therapy...
January 2018: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29374957/protective-effect-of-l-theanine-on-haloperidol-induced-orofacial
#12
Cheng-Neng Chen, Kuo-Chi Chang, Mao-Hsien Wang, Hsiang-Chien Tseng, Hung-Sheng Soung
Tardive dyskinesia (TD) is a severe side effect of chronic neuroleptic treatment consisting of abnormal involuntary movements, characterized by orofacial dyskinesia (OD). Haloperidol (HAL)- induced OD has been widely used as an animal model to study the neuropathophysiology of human tardive dyskinesia (TD) with its pathophysiology strongly associated with striatal oxidative stress. L-Theanine (LT), one of the major amino acid components in green tea, has potent antioxidative effects and is able to protect against various oxidative injuries...
January 29, 2018: Chinese Journal of Physiology
https://www.readbyqxmd.com/read/29374574/gabapentin-reduces-haloperidol-induced-vacuous-chewing-movements-in-mice
#13
Ana Paula Chiapinotto Ceretta, Catiuscia Molz de Freitas, Larissa Finger Schaffer, Jeane Binotto Reinheimer, Mariana Maikéli Dotto, Elizete de Moraes Reis, Rahisa Scussel, Ricardo Andrez Machado-de-Ávila, Roselei Fachinetto
Tardive dyskinesia (TD) is a common adverse effect observed in patients with long-term use of typical antipsychotic medications. A vacuous chewing movement (VCM) model induced by haloperidol has been used to study these abnormalities in experimental animals. The cause of TD and its treatment remain unknown, but several lines of evidence suggest that dopamine receptor supersensitivity and gamma-aminobutyric acid (GABA) insufficiency play important roles in the development of TD. This study investigated the effects of treatment with the GABA-mimetic drug gabapentin on the development of haloperidol-induced VCMs...
January 25, 2018: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/29373456/natural-medicines-for-psychotic-disorders-a-systematic-review
#14
H J Rogier Hoenders, Agna A Bartels-Velthuis, Nina K Vollbehr, Richard Bruggeman, Henderikus Knegtering, Joop T V M de Jong
Patients with psychotic disorders regularly use natural medicines, although it is unclear whether these are effective and safe. The aim of this study was to provide an overview of evidence for improved outcomes by natural medicines. A systematic literature search was performed through Medline, PsycINFO, CINAHL, and Cochrane until May 2015. In 110 randomized controlled trials, evidence was found for glycine, sarcosine, N-acetylcysteine, some Chinese and ayurvedic herbs, ginkgo biloba, estradiol, and vitamin B6 to improve psychotic symptoms when added to antipsychotics...
February 2018: Journal of Nervous and Mental Disease
https://www.readbyqxmd.com/read/29369770/two-new-drugs-for-tardive-dyskinesia-hit-the-market
#15
Thomas Morrow
Ingrezza and Austedo were approved last year. ICER calculations raise questions about their price.
January 2018: Managed Care
https://www.readbyqxmd.com/read/29352477/benzodiazepines-for-antipsychotic-induced-tardive-dyskinesia
#16
REVIEW
Hanna Bergman, Paranthaman S Bhoopathi, Karla Soares-Weiser
BACKGROUND: Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychotic medication stopped or substantially changed, the benzodiazepine group of drugs have been suggested as a useful adjunctive treatment. However, benzodiazepines are very addictive. OBJECTIVES: To determine the effects of benzodiazepines for antipsychotic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder, or other chronic mental illnesses...
January 20, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29345877/comparing-treatments-for-tardive-dyskinesia
#17
Leslie L Citrome
Many treatment interventions for tardive dyskinesia have been studied, but some have better evidence than others. Read this CME activity to get an expert's perspectives on the evidence for older and newer treatments so that you can minimize abnormal movements in your patients.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29345876/assessing-patients-for-tardive-dyskinesia
#18
John M Kane
Do you regularly screen for tardive dyskinesia in at-risk patients? Explore this CME activity by a well-known expert for information on rating scales for screening, available diagnostic criteria, assessment tips, and monitoring recommendations.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29345874/epidemiology-and-prevention-of-tardive-dyskinesia
#19
Christoph U Correll
What risk factors suggest that patients are more likely to develop tardive dyskinesia (TD)? Can TD symptoms be prevented? Read this CME activity to learn about the prevalence, epidemiology, and prevention of these abnormal movements from an expert.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29342497/non-antipsychotic-catecholaminergic-drugs-for-antipsychotic-induced-tardive-dyskinesia
#20
REVIEW
Hany G El-Sayeh, John Rathbone, Karla Soares-Weiser, Hanna Bergman
BACKGROUND: Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known to influence the catecholaminergic system at various junctures. OBJECTIVES: 1...
January 18, 2018: Cochrane Database of Systematic Reviews
keyword
keyword
39290
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"